Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Diabetes. Sep 15, 2026; 17(9): 124151
Published online Sep 15, 2026. doi: 10.4239/wjd.124151
Published online Sep 15, 2026. doi: 10.4239/wjd.124151
Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”
Gu-Lao Zhang, Zhen-Huan Chen, Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330000, Jiangxi Province, China
Author contributions: Zhang GL identified the error in the original figure; Chen ZH reanalyzed the data and made corrections. All the authors have read and approved the final corrected text.
AI contribution statement: No AI tools was used as assistive technologies in this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Zhen-Huan Chen, Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang 330000, Jiangxi Province, China. chenzhenhuan@ncmc.edu.cn
Received: June 9, 2026
Revised: June 22, 2026
Accepted: August 14, 2026
Published online: September 15, 2026
Processing time: 84 Days and 8.5 Hours
Revised: June 22, 2026
Accepted: August 14, 2026
Published online: September 15, 2026
Processing time: 84 Days and 8.5 Hours
Core Tip
Core Tip: In the original publication, the bands of p-AMPK and AMPK in Figure 8A were placed wrongly. This error has now been corrected. In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c”; “&” was incorrect. We apologize for these errors and any confusion that they may have caused.